Sensitivity of patient outcomes to pharmacist interventions. Part III: Systematic review and meta-analysis in hyperlipidemia management

Annals of Pharmacotherapy

Volumn 42, Issue 9, 2008, Pages 1195-1207

  Machado, Márcio ^a   Nassor, Nermine ^b   Bajcar, Jana M ^b   Guzzo, Giovanni C ^c   Einarson, Thomas R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Hyperlipidemia; Patient outcomes; Pharmacist interventions

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; WARFARIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HUMAN; HYPERLIPIDEMIA; META ANALYSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST; PHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; DISEASE MANAGEMENT; HUMANS; HYPERLIPIDEMIAS; PHARMACISTS; PROFESSIONAL ROLE;

EID: 50249144472     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K618     Document Type: Article

References (60)

1. The growing burden of heart disease and stroke in Canada 2003. Ottawa: Heart and Stroke Foundation of Canada, 2003.
2. Heart disease and stroke statistics: 2007 Update At-A-Glance. www.americanheart.org (accessed 2007 Aug 26).
3. World Health Organization. Fact Sheet N 317: Cardiovascular diseases. 2007. www.who.int (accessed 2007 Aug 20).
4. Centers for Disease Control and Prevention. Cholesterol fact sheet. www.cdc.org (accessed 2007 Sept 1).
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11.
7. Hepler C, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
8. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-84.
9. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
10. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 2007;41:1569-82. Epub 21 Aug 2007. DOI 10.1345/aph.1K151
11. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007;41:1770-81. Epub 9 Oct 2007. DOI 10.1345/aph.1K311
12. Barris D, Rodriguez Zarzuelo C, Salinas Munos MM, Sabio Sanchez B, Zarzuelo C. An epidemiological approach to the use of lipid-lowering drugs in a community pharmacy. Pharm Care Esp 2002;4:358-66.
13. Diwan VK, Wahlstrom R, Tomson G, Beermann B, Sterky G, Eriksson B. Effects of group detailing on the prescribing of lipid-lowering drugs: a randomized controlled trial in Swedish primary care. J Clin Epidemiol 1995;48:705-11.
14. Donaldson AR, Andrus MR. Pharmacist-run lipid management program in rural Alabama. Am J Health Syst Pharm 2004;61:493-7.
15. Furmaga EM. Pharmacist management of a hyperlipidemia clinic. Am J Hosp Pharm 1993;50:91-5.
16. Graham MR, Landgraf CG, Lindsey CC. A comparison of orlistat use in a veteran population: a pharmacist-managed pharmacotherapy weight-loss clinic versus standard medical care. J Pharm Technol 2003;19:343-8.
17. Mahtabjafari M, Masih M, Emerson AE. The value of pharmacist involvement in a point-of-care service, walk-in lipid screening program. Pharmacotherapy 2001;21:1403-6.
18. Lalonde L, O'Connor AM, Drake E, Duguay P, Lowensteyn I, Grover SA. Development and preliminary testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular disease. Pharmacotherapy 2004;24:909-22.
19. Madejski RM, Madejski TJ. Cholesterol screening in a community pharmacy. J Am Pharm Assoc 1996;NS36:243-8.
20. O'Donnel DC, Chen NTW, Piziak VK. Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic. Am J Health Syst Pharm 2001;58:325-30.
21. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
22. Vaillancourt R, Gutschi LM, Ma J, Sinclair S, Beechimor D. Pharmacist-managed lipid clinics: development and implementation in the Canadian Forces. Can J Hosp Pharm 2003;56:24-31.
23. Ono GH. Pharmacist management of hyperlipidemia. Cal J Health Syst Pharm 1998;10:24-6.
24. Shilbayeh S. Management of hyperlipidemia and the urgency for the effective therapeutic drug monitoring. Jordan J Appl Sci 2003;5:1-25.
25. Shintoh M, Iwakawa S, Shimada Y, Fujita M, Konishi KI. Effects of pharmacists' consultation on serum cholesterol level using drug history notebook or drug instruction sheets for outpatients with hypercholesterolemia. Jap J Pharm Health Care Sci 2001;27:337-42.
26. Sternhagen V, Sesing C. Hyperlipidemia and LDL-C goal attainment in a cardiology clinic. J Pharm Soc Wis 2003;(Sep-Oct):28-9.
27. Wahlstrom R, Tomson G, Diwan VK, Beermann B, Sterky G. Hyperlipidaemia in primary care - a randomized controlled trial on the treatment information in Sweden: design and methodology. Pharmacoepidemiol Drug Saf 1995;4:75-90.
28. Bradberry JC, Srnka Q, Hutchison LC. Pharmacist-assisted self-care to lower lipid levels and CHD risks. Pharm Times 2002(April);68:50-6.
29. Cross LB, Frank AS. Clinical outcomes associated with pharmacist involvement in patients with dyslipidemia: a review. Dis Manag Health Outcomes 2005;13:31-42.
30. Ito MK. Counseling patients concerning cholesterol-lowering therapy: the pharmacist role. Pharm Times 2003(May);69:10-2.
31. Olson KL, Potts LA. Role of the pharmacist in the management of dyslipidemia. J Pharm Pract 2006;19:94-102.
32. Carson JJ. Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults. Am J Health Syst Pharm 1999;56:2319-24.
33. Taylor CT, Byrd DC, Krueger K. Improving primary care in rural Alabama with pharmacy initiative. Am J Health Syst Pharm 2003;60:1123-9.
34. Birnbaum U, Schaefer M, Verheyen F, Schulz M, Mast O, Evers T. Pharmaceutical care of patients with lipid metabolic disorders. Pharm Ztg 2003;148:30-5.
35. Cheng CWR, Woo KS, Chan JCN, Tomlinson B, You JHS. Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device. Am J Health Syst Pharm 2005;62:411-5.
36. Hilleman DE, Faulkner MA, Monaghan MS. Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia. Pharmacotherapy 2004;24:1077-83.
37. Johnson TM. On the front lines of pharmaceutical care: lipid management at an Indian health service clinic. Consult Pharm 1998;13:886-7.
38. Ali F, Laurin MY, Lariviere C, Tremblay D, Coutier D. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol 2003;10:101-6.
39. Alldred DP, Booth C, Chrystyn H. Development of pharmacist-led cholesterol screening and lipid-lowering medication review service in coronary artery bypass graft patients. Int J Pharm Pract 2001;9:275-81.
40. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
41. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
42. Cardo Prats E, Corella Piquer MD, Garcia Cebrian F, Manes Vinuesa J. Pharmaceutical care in hyperlipidemic drug patients. Pharm Care Esp 2001;3:95-104.
43. Collins C, Kramer A, O'Day ME, Low MB. Evaluation of patient and provider satisfaction with a pharmacist-managed lipid clinic in a Veterans Affairs medical center. Am J Health Syst Pharm 2006;63:1723-7.
44. Cording MA, Engelbrecht-Zadvorny EB, Pettit BJ, Eastham JH, Sandoval R. Development of a pharmacist-managed lipid clinic. Ann Pharmacother 2002;36:892-904. DOI 10.1345/aph.1A158
45. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE Study. Pharmacotherapy 2000;20:1508-16.
46. Geber J, Parra D, Beckey NP, Norman L. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy 2002;22:738-47.
47. Konzem SL, Gray DR, Kashyap ML. Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veterans. Pharmacotherapy 1997;17:576-83.
48. Lee SS, Cheung PY, Chow MS. Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong. J Clin Pharmacol 2004;44:632-9.
49. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA medical centers. J Manag Care Pharm 2005;11:763-71.
50. Nola KM, Gourley DR, Portner TS, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc 2000;40:166-73.
51. Paulós CP, Akesson Nygren CE, Celedón C, Cárcamo CA. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Ann Pharmacother 2005;39:939-43. Epub 12 Apr 2005. DOI 10.1345/aph.1E347
52. Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Stewart K, Krum H. Impact of pharmacist-conducted home visits on the outcome of lipid-lowering drug therapy. J Clin Pharm Ther 2004;29:23-30.
53. Rehring TF, Stolcpart RS, Sandhoff BG, Merenich JA, Hollis HW Jr. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg 2006;43:1205-10.
54. Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med 1995;155:2330-5.
55. Shibley MC, Pugh CB. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacist practitioners. Ann Pharmacother 1997;31:713-9.
56. Straka RJ, Taheri R, Cooper SL, Smith JC. Achieving cholesterol target in a managed care organization (ACTION) trial. Pharmacotherapy 2005;25:360-71.
57. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacy management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm 2003;9:269-73.
58. Vrijens B, Belmans A, Matthys K, de Klerk E, Lesaffre E. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 2006;15:115-21.
59. Yamada C, Johnson JA, Robertson P, Pearson G, Tsuyuki RT. Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Pharmacotherapy 2005;25:110-5.
60. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563-71.